Bionano Genomics, Inc. Warrant
BNGOW
BNGOW was delisted on the 17th of August, 2023.
3 hedge funds and large institutions have $23K invested in Bionano Genomics, Inc. Warrant in 2022 Q2 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 1 reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 3 → 3 (0)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
57% less capital invested
Capital invested by funds: $53K → $23K (-$30K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$1.65K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PFM
Privium Fund Management
Amsterdam,
Netherlands
|
-$2.51K |
BNGOW Hedge Fund Activity: Q2 2022 in Review
3 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Bionano Genomics, Inc. Warrant (BNGOW) for Q2 2022, worth a combined $23K — down 57% from $53K a quarter earlier.
Fund positioning in BNGOW was balanced in Q2 2022: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 1 trimmed.
The largest buyer was UBS Group, adding an estimated $1.65K. The largest seller was Privium Fund Management, cutting an estimated $2.51K.
- 3 institutional investors held Bionano Genomics, Inc. Warrant (BNGOW) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $23K of Bionano Genomics, Inc. Warrant stock for Q2 2022, down 57% quarter-over-quarter.
- 0 funds opened new Bionano Genomics, Inc. Warrant positions in Q2 2022 and 0 closed out.
- The largest Bionano Genomics, Inc. Warrant buyer in Q2 2022 was UBS Group, an estimated $1.65K added.
- The largest Bionano Genomics, Inc. Warrant seller in Q2 2022 was Privium Fund Management, an estimated $2.51K sold.
Based on aggregated 13F filings for Q2 2022.